title: Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease.
abstract: BACKGROUND
  Controlled clinical trials have demonstrated the efficacy and safety of adalimumab in patients with moderate-to-severe Crohn's disease (CD), but there is, however, only limited long-term experience with adalimumab in daily practice.
  
  
  OBJECTIVE
  To assess the long-term effectiveness and safety of adalimumab in a multicenter cohort of practice-based patients with moderate-to-severe CD.
  
  
  METHODS
  We retrospectively reviewed the charts of CD patients who received adalimumab over a 3-year period. Disease severity was scored using the Harvey-Bradshaw index (HBI). Remission was defined as an HBI of <or=4 and response as a reduction in the HBI of >3 points at evaluation compared to the baseline. Univariate logistic regression analysis was used to identify the predictive variables associated with response.
  
  
  RESULTS
  The charts of 55 patients were reviewed; remission and response rates observed at weeks 4-6 were 52.7 and 83.6%, respectively. Remission was maintained at weeks 12, 24 and 52 in 89.6, 72.4 and 44.7% of patients, respectively. Remission and response rates were not influenced by smoking status, disease location or duration, the first month total dose, or previous infliximab therapy. The remission rate at weeks 4-6 was significantly higher in patients intolerant of infliximab as compared to those who lost response to this drug. Adalimumab was well tolerated overall.
  
  
  CONCLUSIONS
  Adalimumab can be considered a suitable option in patients with moderate-to-severe CD, demonstrating sustained long-term effectiveness.
authors.affiliation: Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
authors.forename: Cristina
authors.initials: C
authors.lastname: Nichita
authors.forename: Marc
authors.initials: M
authors.lastname: Stelle
authors.forename: Stephan
authors.initials: S
authors.lastname: Vavricka
authors.forename: Abdou
authors.initials: A
authors.lastname: El-Wafa Ali
authors.forename: Pierluigi
authors.initials: P
authors.lastname: Ballabeni
authors.forename: Philippe
authors.initials: P
authors.lastname: de Saussure
authors.forename: Alex
authors.initials: A
authors.lastname: Straumann
authors.forename: Gerhard
authors.initials: G
authors.lastname: Rogler
authors.forename: Pierre
authors.initials: P
authors.lastname: Michetti
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000069285:Infliximab; D016015:Logistic Models; D008297:Male; D010641:Phenotype; D012189:Retrospective Studies; D012720:Severity of Illness Index; D012907:Smoking / Q000009:adverse effects; D013557:Switzerland; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069285:Infliximab; D000068879:Adalimumab